HGG-21. GERMLINE MUTATIONS IN MSH2 GENE IN PEDIATRIC PATIENTS WITH CONGENITAL AND SPORADIC GLIOBLASTOMA

INTRODUCTION: Glioblastoma (GBM) remains one of the biggest therapeutic challenges in neuro-oncology. In spite of multimodal treatment approaches the prognosis of GBM is extremely poor, median survival is estimated about 12–16 months. Although GBM is one of the most common and malignant primary brai...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Ejmont, Maria, Rydzanicz, Małgorzata, Grajkowska, Wiesława, Perek-Polnik, Marta, Sowińska, Agnieszka, Kozłowska, Magdalena, Łastowska, Maria, Pronicki, Maciej, Płoski, Rafał, Dembowska-Bagińska, Bożenna, Trubicka, Joanna
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2020
Materias:
High Grade Glioma
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7715741/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa222.308
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares